{
    "2021-06-16": [
        [
            {
                "time": "2021-06-08",
                "original_text": "Should I Buy Eli Lilly and Company (LLY)?",
                "features": {
                    "keywords": [
                        "Eli Lilly",
                        "buy",
                        "LLY"
                    ],
                    "sentiment_score": 0.5,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "pharmaceuticals"
                    ],
                    "causal_factor": "false",
                    "causal_impact": "neutral",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2021-06-08",
                "original_text": "Biogen Alzheimer’s drug approval was 'surprising for a lot of people': Eli Lilly CEO",
                "features": {
                    "keywords": [
                        "Biogen",
                        "Alzheimer’s",
                        "drug",
                        "approval",
                        "surprising",
                        "Eli Lilly",
                        "CEO"
                    ],
                    "sentiment_score": 0.7,
                    "policy_related": "true",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "pharmaceuticals",
                        "healthcare"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2021-06-08",
                "original_text": "FDA ‘shifting the bar’ for approval with new Alzheimer’s drug: Eli Lilly CEO",
                "features": {
                    "keywords": [
                        "FDA",
                        "shifting",
                        "bar",
                        "approval",
                        "Alzheimer’s",
                        "drug",
                        "Eli Lilly",
                        "CEO"
                    ],
                    "sentiment_score": 0.6,
                    "policy_related": "true",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "pharmaceuticals",
                        "regulatory"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            }
        ]
    ]
}